Medical terminology

Medical Database, Inc. Integrates Its Laboratory Decision System, LDS®, With Allscripts TouchWork

Retrieved on: 
Wednesday, July 21, 2021
Health informatics, Health, Computerized physician order entry, Medical terminology, Medical necessity, Allscripts, Medicare

IRVINE, Calif., July 21, 2021 /PRNewswire/ --Medical Database, Inc., an innovative provider of clinical laboratory and medical content, today announced the successful integration of its laboratory decision system, LDS, with Allscripts TouchWorks.

Key Points: 
  • IRVINE, Calif., July 21, 2021 /PRNewswire/ --Medical Database, Inc., an innovative provider of clinical laboratory and medical content, today announced the successful integration of its laboratory decision system, LDS, with Allscripts TouchWorks.
  • Through integration with Allscripts, the Company has launched a Computerized Provider Order Entry (CPOE) specifically designed to help providers order the right test(s) for any given disease by meeting the medical necessity and, thereby improve reimbursement rates.
  • Every order submitted using the Company's CPOE automatically will include the correct ICD10 and CPT codes and will be checked for Medicare LCDs and NCDs to ensure medical necessity is met.
  • Our content, written and curated by medical professionals, comprises a range of medical databases to assist healthcare providers in making appropriate clinical decisions, meeting medical necessity, and maintaining compliance.

FAIR Health Awarded Grant from The John A. Hartford Foundation to Advance Cost Information in Shared Decision Making for Serious Illnesses

Retrieved on: 
Wednesday, July 21, 2021
Health, Articles, Health care, Health policy, Caregiver, Unpaid work, Health system, Medical terminology, Shared decision-making in medicine, Health care quality

SDM tools, such as decision aids, also may reduce unnecessary spending in healthcare for both patients and providers.

Key Points: 
  • SDM tools, such as decision aids, also may reduce unnecessary spending in healthcare for both patients and providers.
  • FAIR Health will pilot the new tools and evaluate their perceived utility and value among relevant patient and caregiver populations.
  • FAIR Health President Robin Gelburd said of the project: "We at FAIR Health are grateful to The John A. Hartford Foundation for supporting this important initiative that will build on our efforts to thread cost information into key healthcare decision-making discussions.
  • The Foundation has three priority areas: creating age-friendly health systems, supporting family caregivers and improving serious illness and end-of-life care.

Customer Experience Gap Jeopardizes Recovery of Elective Healthcare Business

Retrieved on: 
Wednesday, July 21, 2021
Health care quality, Medical terminology, Patient

PHOENIX, July 21, 2021 /PRNewswire-PRWeb/ --A nationwide survey of 617 recent and prospective patients for elective procedures finds serious holes in providers' approach to the patient experience that could jeopardize the recovery of the elective treatment business.

Key Points: 
  • PHOENIX, July 21, 2021 /PRNewswire-PRWeb/ --A nationwide survey of 617 recent and prospective patients for elective procedures finds serious holes in providers' approach to the patient experience that could jeopardize the recovery of the elective treatment business.
  • Elective Healthcare Modern Patient Insights Report 2021 from healthcare marketer LaneTerralever and CX consultancy Convince and Convert finds that 66% of patients had to delay elective procedures during the pandemic, and 39% of them don't plan to reschedule.
  • "Healthcare providers need to re-examine the patient journey from the endpoint, because the dissatisfactions that jeopardize elective treatment business aren't solved by traditional marketing efforts," added Hillery.
  • "The smallest thing a patient feels dissatisfied about during their post-op experience could change the entire trajectory of their reflection on that experience."

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Retrieved on: 
Wednesday, July 21, 2021
Medicine, Medical tests, Branches of biology, Clinical medicine, Medical terminology, Immunologic tests, Chromatography, Molecular biology, Rapid antigen test, COVID-19, Point-of-care testing

HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembio’s delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio’s supply chain, staffing, and liquidity, and other matters outside Chembio’s control.

Key Points: 
  • The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab.
  • Chembio has a long-standing relationship with Bio-Manguinhos, having supplied multiple products for point-of-care detection of COVID-19 antibodies, HIV, and other infectious diseases.
  • We believe the purchase order validates the investments we made earlier this year in inventory for the DPP SARS-CoV-2 Antigen test and look forward to ramping up production.
  • Chembios portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA).

Newtopia Delivers Expanded Mental Health Offerings for Health Insurers

Retrieved on: 
Tuesday, July 20, 2021
Medical terminology, Health sciences, Medicine, Articles, Preventive healthcare, Chronic condition, Disease, Mental health
Key Points: 
  • Newtopia focuses on whole person health, the belief that physical and mental health must be evaluated together to prevent, reverse and slow the progression of chronic disease.
  • These new mental health offerings will be part of the existing Newtopia experiences, which include Weight Management, Diabetes Prevention, MetS/Disease Prevention, Hypertension and Heart Health and Healthy Living with Diabetes.
  • Newtopia's two new mental health offerings were developed in the Newtopia Innovation Lab.
  • "It is clear that on their own, solutions for physical health or mental health improvement will never create sustainable change and in turn generate significant cost savings for health insurers and other risk bearing entities.

Rapid-Ease Offers Fast Pain Relief

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Pharmacology, Health, Dosage forms, Acute pain, Ointments, Medical terminology, Topical medication, Pain management, Pain, Cream

FORT LAUDERDALE, Fla., July 20, 2021 /PRNewswire/ --Rapid-Ease is a brand that has made its name in the pain relief industry.

Key Points: 
  • FORT LAUDERDALE, Fla., July 20, 2021 /PRNewswire/ --Rapid-Ease is a brand that has made its name in the pain relief industry.
  • The brand's Rapid-Ease Pain Relief Cream brings a particularly potent list of herbal ingredients delivered in therapeutic levels designed to genuinely "help you heal naturally."
  • Davies-Haycock's brands are founded on a commitment to creating fast-acting, effective topical pain relief products.
  • As a topical product, Rapid-Ease Pain Relief Cream has been carefully formulated by renowned natural cosmetic chemist Susan Hall to maximize absorption through a unique penetration system.

Guideway Care Signs National Agreement with Vizient, Inc. for Care Guidance Services

Retrieved on: 
Tuesday, July 20, 2021
Health care, Health, Medical terminology, Health care quality, Adherence, Clinical pharmacology, Pharmacy, Vizient, Inc., Nursing

BIRMINGHAM, Ala., July 20, 2021 /PRNewswire-PRWeb/ -- Guideway Care (Guideway), a leader in technology-enabled care guidance services that extend beyond mere navigation, announced the launch of a multi-year agreement with Vizient, Inc. (Vizient).

Key Points: 
  • BIRMINGHAM, Ala., July 20, 2021 /PRNewswire-PRWeb/ -- Guideway Care (Guideway), a leader in technology-enabled care guidance services that extend beyond mere navigation, announced the launch of a multi-year agreement with Vizient, Inc. (Vizient).
  • "With rising performance pressures, higher barriers to care, and nursing and staff shortages, addressing the practical barriers faced by patients across the care journey has become more critical.
  • Patients are often non-compliant with prescribed care paths because of practical, social, and emotional factors that can be resolved by non-clinical Care Guides.
  • Once on a care pathway, our team and technology fill gaps in care to drive compliance, better patient communication, and patient satisfaction.

Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Health, Medicine, Medical terminology, Progression-free survival, Clinical endpoint, Survival rate

Approximately 160 patients are expected to be randomized in a 1:1 ratio to receive milademetan or trabectedin.

Key Points: 
  • Approximately 160 patients are expected to be randomized in a 1:1 ratio to receive milademetan or trabectedin.
  • The primary objective of the trial is to compare progression-free survival (PFS) by blinded independent review between the milademetan treatment arm and the trabectedin control arm.
  • Secondary endpoints include overall survival, PFS by investigator assessment, objective response rate, duration of response, disease control rate, safety and patient reported outcomes.
  • As of July 1, 2021, three WD/DD LPS patients received therapy with milademetan monotherapy for greater than 51 months.

State of Delaware Selects Quidel for COVID-19 Testing Program at Schools

Retrieved on: 
Monday, July 19, 2021
Other Health, General Health, Pharmaceutical, Data management, Preschool, Medical devices, Technology, Other Education, Infectious diseases, Primary, Secondary, Education, Health, Medicine, Natural sciences, Branches of biology, Medical tests, Medical terminology, Quidel Corporation, Biotechnology, Chromatography, Molecular biology, Rapid diagnostic test, Rapid antigen test, COVID-19 testing

Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
  • Students and faculty that opt-in to the COVID-19 screening program will be tested with Quidels rapid antigen tests.
  • DPH and Delawares Department of Education will launch the initiative at five pilot schools for summer school enrollees.
  • Quidel can expand the program to all of the States K-12 schools when classrooms fully reopen for the fall semester.

Sweetch Secures $20 Million Series A to Accelerate Fully Automated Hyper-personalized Engagement Between Health Ecosystem Players and People with Chronic Conditions

Retrieved on: 
Monday, July 19, 2021
Health, Medical terminology, Health care quality, Health informatics, Health care management, Chronic condition, Adherence, Disease management

90 percent of healthcare costs in the US are attributable to chronic diseases, which afflict 50 percent of the population.

Key Points: 
  • 90 percent of healthcare costs in the US are attributable to chronic diseases, which afflict 50 percent of the population.
  • This seemingly contradictory statement can be achieved through technology like Sweetch," said Dr. Doron Dinstein, Venture Partner at Entre Capital.
  • Sweetch provides a hyper-personalized, scalable and cost-effective solution to increase patient adherence across various aspects of disease management and improve clinical outcomes for people with chronic conditions.
  • Sweetch is the developer of hyper-personalized engagement solutions for chronic conditions.